“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 25/03/2023
EUR9.95
▲ 0.28 (2.90%)
Market capitalisation
EUR36m
SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
Consumer
Consumer
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (10.0) | (4.1) | (47.1) |
| Relative | (9.0) | (12.3) | (49.7) |
| 52 week high/low | €20.8/€9.0 |
SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.
Get access to the very latest content matched to your personal investment style.
